Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Dose-escalation, Dose-optimization and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101/GI-101A as a Single Agent and in Combination With Pembrolizumab or Lenvatinib in Patients With Advanced or Metastatic Solid Tumors (Keynote B59)

NCT04977453 is registered in ClinicalTrials.gov with GI Innovation, Inc. as lead sponsor.

NCT NCT04977453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04977453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Dose-escalation, Dose-optimization and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101/GI-101A as a Single Agent and in Combination With Pembrolizumab or Lenvatinib in Patients With Advanced or Metastatic Solid Tumors (Keynote B59)
Lead sponsor
GI Innovation, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 2, 2021
Completion date
June 30, 2028
Enrollment
317 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cervical cancer, clear cell renal cell cancer (ccrcc), metastatic solid tumor, squamous cell non small cell lung cancer, urothelial carcinoma